# Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer

> **NCT00072319** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center**

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** cyclophosphamide
- **DRUG:** epirubicin hydrochloride
- **DRUG:** paclitaxel
- **PROCEDURE:** adjuvant therapy
- **PROCEDURE:** neoadjuvant therapy

## Key facts

- **NCT ID:** NCT00072319
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** 2006-11
- **Final completion:** 2006-11
- **Target enrollment:** — (—)
- **Last updated:** 2013-03-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00072319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00072319, "Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00072319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*